Windtree Therapeutics, Inc.
News
Windtree Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic Shock
Globe Newswire Topline data anticipated in late September 2024WARRINGTON, Pa., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ( Windtree or the Company ) (NasdaqCM: WINT), a biotechnology...\n more…
Critical Contrast: Windtree Therapeutics (NASDAQ:WINT) versus ZIVO Bioscience (NASDAQ:ZIVO)
Zolmax ZIVO Bioscience (NASDAQ:ZIVO - Get Free Report) and Windtree Therapeutics (NASDAQ:WINT - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast...\n more…
Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Down 56.8% in August
Ticker Report Windtree Therapeutics, Inc. (NASDAQ:WINT - Get Free Report) was the recipient of a significant decrease in short interest in the month of August. As of August 15th, there was short interest totalling...\n more…
Analyzing Windtree Therapeutics (NASDAQ:WINT) & ZIVO Bioscience (NASDAQ:ZIVO)
Ticker Report Windtree Therapeutics (NASDAQ:WINT - Get Free Report) and ZIVO Bioscience (NASDAQ:ZIVO - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two...\n more…
